Skip to content

Evaluation Of The Efficacy of AYUSH KWATH in The Prevention of COVID-19

Evaluation Of The Efficacy of AYUSH KWATH in The prevention of COVID-19 pandemic among persons residing in hot spot area â?? An open label single arm prospective study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2020/07/026355
Enrollment
500
Registered
2020-07-04
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: AYUSH KWATH: Dose : 3 gm daily mixed with 150 ml warm water Route of Administration : Oral Time of Administration : Once in a day- On empty stomach in the morning at least 1 hour befo

Sponsors

Dr SR Rajasthan Ayurved University Jodhpur
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All persons residing in hotspot areas of covid 19 willing to participate, with or without co- morbid condition with exposure/chance of exposure to COVID 19 positive cases. . Who are willing to provide signed informed consent

Exclusion criteria

Exclusion criteria: 1. Pregnant females. 2. Known case of Carcinoma lungs, CRF and CHF. 3. Participants with any immunosuppressive medication or in an immune compromised state or hematological disease. 4. Laboratory confirmed COVID-19 with or without symptoms. 5. DM uncontrolled with medications. 6. Any other criteria, as per the investigator would jeopardize the study.

Design outcomes

Primary

MeasureTime frame
Percentage of participants with SARS- Cov-2 positivity and Number/ percentage of participants not developing any Covid-19 like sign & symptoms (Time line 07 days)Timepoint: Percentage of participants with SARS- Cov-2 positivity and Number/ percentage of participants not developing any Covid-19 like sign & symptoms (Time line 07 days)

Secondary

MeasureTime frame
Presence or absence of AE/ADR and their level of tolerability Number of participants who developed any infective diseases during the trial period (bacterial /viral/ fungal / etc.) and percentage of participants with Upper respiratory tract illness during the period. Timepoint: 07 days

Countries

India

Contacts

Public ContactProf Dr Abhimanyu Kumar

Dr. S.R. Rajasthan Ayurved University, Jodhpur

vc.dsrrau@gmail.com8800543828

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026